Lapatinib: a sword with two edges (Q37137696)

18 August 2017

1 reference

title

Lapatinib: a sword with two edges (English)

1 reference

18 August 2017

László Kopper

1

1 reference

18 August 2017

1 March 2008

1 reference

Pathology Oncology Research

18 August 2017

1 reference

18 August 2017

14

1 reference

18 August 2017

1

1 reference

18 August 2017

1-8

1 reference

https://scigraph.springernature.com/pub.10.1007/s12253-008-9018-z

18 August 2017

0 references

cites work

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12253-008-9018-Z

Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification

21 January 2018

1 reference

12 December 2020

The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer

1 reference

12 December 2020

Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy

1 reference

12 December 2020

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials

1 reference

12 December 2020

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

12 December 2020

Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles

1 reference

12 December 2020

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

1 reference

12 December 2020

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

Molecular targeted therapies in breast cancer: where are we now?

1 reference

12 December 2020

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

1 reference

12 December 2020

1 reference

12 December 2020

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

1 reference

12 December 2020

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

1 reference

12 December 2020

Lapatinib in breast cancer

1 reference

12 December 2020

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

1 reference

12 December 2020

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

1 reference

12 December 2020

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

1 reference

12 December 2020

Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors

1 reference

12 December 2020

Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies

1 reference

12 December 2020

Biology of interactions: antiepidermal growth factor receptor agents

1 reference

12 December 2020

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

12 December 2020

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan

1 reference

12 December 2020

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

1 reference

12 December 2020

10.1007/S12253-008-9018-Z

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18409020